
Featured Track:
Life Cycle Management, Line Extensions and New Development Strategies for Continued Profitability
Chair: Dr. Ralph Lipp, Former Vice President, Pharmaceutical Sciences R&D, ELI LILLY
Evaluating Platform Technologies in Lieu of Single Molecule Technologies:
When it comes to finding the perfect technology, it’s often a question of macro vs. micro usage. The big question: focus on a cross-platform approach or drill down to a specific molecular application?
In this session, executives:
• Evaluate the ability to determine technologies for large and small molecules at the same time
• Discuss whether testing can occur before phase 3
• Explain how drug delivery companies can aid in the decision-making process
-Julia Rashba-Step, Senior Director, Novel Delivery Technologies, Biotherapeutics R&D, PFIZER
-Keith Horspool, Vice President, Pharmaceutics, BOEHRINGER INGELHEIM
Create Value through Alternate-Route Delivery
This session, lead by Ronald Smith, Executive Director and Head, Product Value Enhancement, MERCK answers the questions:
• What is the strategy behind alternate-route delivery?
• How do you show the value?
• When do you begin the process relative to the molecule and therapeutic area?
Additional Life Cycle Management Sessions Include:
• Create a new OTC brand with Novel Drug Delivery
• Fixed Dose Combinations: Use Predictive Studies to Establish Potential for Success or Failure
• Overcome Challenges Associated with the Development of Drug Delivery-based Generics
• Quicker Feasibility Studies to Speed Up Technology Assessment
To view the 2013 program, download the agenda.
As a reader of the Drug Delivery Partnerships Internationalblog, you get a 15% discount off the standard rate when using code XP1878BLOG to register. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.
Cheers,
The Drug Delivery Partnerships International Team
The DDP Homepage
DDP Twitter
No comments:
Post a Comment